STOCK TITAN
  1. Home
  2. News
  3. BNGO

Bionano Genomics, Inc. - BNGO STOCK NEWS

Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.

Bionano Genomics, Inc. (Nasdaq: BNGO) is a pioneering company in the life sciences instrumentation sector, dedicated to advancing genome biology understanding through innovative solutions. The company is renowned for its development and marketing of the Saphyr™ system, an ultra-sensitive platform designed for structural variation detection. This system enables researchers and clinicians to accelerate diagnostics and therapeutic target discovery, streamlining studies on chromosomal changes.

Bionano's core mission is to transform genomic analysis through optical genome mapping (OGM) solutions, diagnostic services, and software. Their flagship product, Saphyr™, offers unmatched capabilities in structural variation discovery and the ability to construct comprehensive genome assemblies. This technology is crucial for applications in cancer research, human disease studies, agricultural bioengineering, and genome discovery.

Recent achievements include the detection of unique structural variations and gene fusions in blood cancer samples, underscoring OGM's potential as a complement to traditional sequencing methods. Bionano's OGM technology has shown superior sensitivity and resolution in various studies, highlighting its utility in pediatric leukemia and other cancers.

The company operates globally with significant revenue from the Americas, and it generates product revenue from the sales of OGM and Ionic Purification systems and consumables. Bionano also offers diagnostic testing for neurodevelopmental disabilities through its Lineagen, Inc. d/b/a Bionano Laboratories business and industry-leading genome analysis software that integrates next-generation sequencing and microarray data.

Partnerships with AI-driven companies like Diagens further enhance Bionano's offerings, aiming to improve reproductive health and other clinical applications. Additionally, Bionano continuously upgrades its VIA software and Bionano Solve pipeline to provide researchers with precise and sensitive genomic research tools.

For more information, visit Bionano Genomics and its associated websites, www.bionanolaboratories.com and www.purigenbio.com.

News

Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024

Rhea-AI Summary
Bionano Genomics, Inc. reported a strong financial performance for Q4 2023 and FY 2023, with revenue growth of 30% over the previous year, reaching $10.7 million and $36.1 million, respectively. The company achieved significant milestones in OGM system installations and flowcell sales, indicating a 36% increase in installed systems and a 72% increase in flowcells sold compared to the previous year. Key product launches such as the Stratys system and VIA software have been well-received, driving revenue growth. Bionano also saw positive clinical validation results for OGM in prenatal and postnatal studies. The company aims to continue its success in 2024 by focusing on core OGM products, anticipating revenue in the range of $37.0 to $41.0 million for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
earnings
-
News

Bionano to Present at TD Cowen’s 44th Annual Health Care Conference

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced that Erik Holmlin, CEO, will present at TD Cowen's Health Care Conference on March 6, 2024. The webcast will be available on their website for 30 days post-conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences
-
News

Bionano to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) will host a conference call to report financial results for Q4 and year end 2023, highlighting recent corporate progress. The call will take place on March 5, 2024, at 4:30 p.m. ET. Participants can access the live webcast on the company's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
conferences earnings
News

Bionano Announces Amendment to Debt Financing Arrangement to Extend Cash Runway

Rhea-AI Summary
Bionano Genomics, Inc. announces an amendment to reduce outstanding debt through convertible notes, providing immediate access to $30.0 million of near-term liquidity. The company aims to expand capital and reduce debt on its balance sheet, enhancing financial flexibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
News

American College of Medical Genetics and Genomics Includes OGM in Latest Edition of Technical Laboratory Standards for Solid Tumor Analysis

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announces the inclusion of optical genome mapping (OGM) in the ACMG technical laboratory standards for solid tumor analysis. OGM's high-resolution detection of structural variants is highlighted, emphasizing its utility in genome-wide analysis for solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
-
News

Bionano to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced that its CEO will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13-14, 2024. Interested parties can schedule a meeting with Bionano through their BTIG representative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
conferences
News

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Rhea-AI Summary
Bionano Genomics, Inc. concluded its 2024 Symposium, featuring 32 oral presentations and 69 scientific posters from 92 countries. The event showcased the potential of optical genome mapping (OGM) in research applications for hematologic malignancies, genetic diseases, and cell and gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
News

Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced a peer-reviewed publication in Cancers detailing the use of optical genome mapping (OGM) to discover structural variants (SVs) driving drug resistance and sensitivity in cancer. The study analyzed 26 leukemia samples, revealing drug sensitivities and resistances associated with genomic rearrangements. OGM detected all SVs observed using classical cytogenetic methods and additional variants. The findings suggest potential new treatment strategies for leukemia, with implications for drug development and personalized medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of the second interim report from an ongoing clinical trial designed to support establishing OGM as part of standard of care (SOC) in the diagnosis of genetic disease for prenatal subjects. The study demonstrated that OGM has high sensitivity, specificity, and overall accuracy, making it a promising alternative to classical cytogenetic methods in prenatal diagnosis. The results of the study show that OGM can provide results comparable to two or three separate standard of care tests with just a single assay, indicating its potential to streamline genetic analysis processes and provide rapid, cost-effective solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
clinical trial
News

Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) has announced the full commercial release of the Stratys™ system, a high throughput optical genome mapping (OGM) system. The Stratys instrument offers up to a four-fold increase in raw data generation rate compared to the Saphyr® instrument and can process up to 12 single access chips without the need to batch multiple samples on a consumable. The data analysis for the Stratys system is powered by Stratys™ Compute, developed in collaboration with NVIDIA. 10 users across Canada, the United States, Europe, and Saudi Arabia have adopted a total of 11 Stratys systems as part of an early access program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Bionano Genomics (BNGO)?

The current stock price of Bionano Genomics (BNGO) is $0.2266 as of January 10, 2025.

What is the market cap of Bionano Genomics (BNGO)?

The market cap of Bionano Genomics (BNGO) is approximately 31.7M.

What does Bionano Genomics, Inc. specialize in?

Bionano Genomics specializes in genome analysis solutions, particularly through their Saphyr™ system for structural variation detection.

What is the Saphyr™ system?

The Saphyr™ system is Bionano's high-speed, high-throughput whole genome mapping solution that offers unmatched structural variation discovery capabilities.

What are the applications of Bionano's OGM technology?

Bionano's OGM technology is used in cancer research, human disease studies, agricultural bioengineering, and genome discovery.

What recent achievements has Bionano reported?

Bionano recently reported detecting unique structural variations and gene fusions in blood cancer samples, showcasing OGM's potential as a complement to traditional sequencing methods.

Where does Bionano operate?

Bionano operates globally with significant revenue generated from the Americas, EMEA, and Asia Pacific regions.

What additional services does Bionano offer?

Bionano offers diagnostic testing for neurodevelopmental disabilities and industry-leading genome analysis software that integrates next-generation sequencing and microarray data.

Who are Bionano's key partners?

Bionano partners with companies like Diagens to enhance clinical applications, particularly in reproductive health.

What is the purpose of Bionano's VIA software?

Bionano's VIA software provides researchers with precise and sensitive tools for genomic research, improving visualization, interpretation, and reporting of results.

Are Bionano's products for research or clinical use?

Most of Bionano’s OGM products are for research use only and not for use in diagnostic procedures.

How can I learn more about Bionano Genomics?

You can visit Bionano's main website at www.bionano.com or its associated websites, www.bionanolaboratories.com and www.purigenbio.com, for more information.
Stock BNGO logo
Bionano Genomics, Inc.

Nasdaq:BNGO

BNGO Rankings

#5144 Ranked by Market Cap
N/A Ranked by Dividends

BNGO Stock Data

31.68M
139.65M
0.15%
12.81%
10.25%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO